The prognostic role of baseline F-18-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy

Basit Öğe Kaydı
dc.authorid0000-0003-3878-988Xen_US
dc.authorid0000-0002-7451-2786en_US
dc.contributor.authorCan, Canan
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKömek, Halil
dc.contributor.authorGündoğan, Cihan
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorIşıkdogan, Abdurrahman
dc.date.accessioned2023-03-03T12:57:18Z
dc.date.available2023-03-03T12:57:18Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.description.abstractObjective: This study aimed to determine the prognostic role of baseline maximum standardized uptake value (SUVmax) obtained by pretreatment PET/CT and the change in SUVmax ( ASUVmax [90]) in patients with axillary lymph node -positive breast cancer receiving neoadjuvant chemotherapy (NAC). Methods: One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAl) and the change in the SUVmax of the breast (ASUVmaxp,) and axilla (ASUVmaxA) were measured. The optimal cut-off value of SUVmax and ASUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan -Meier curves. Results: \SUVmax5, pCRB, pCRA, and pCR parameters were found to be associated with relapse (P<.001, P=.033, P=.016, and P=.013, respectively). ASUVmaxB and SUVmaxAl were associated with mortality (P=.001 and P=.006, respectively). Multiple Cox regression analyses revealed that \SUVmax5 value was an independent prognostic factor for relapse and mortality (P=.013 and P=.010, respectively). Conclusion: The results showed that ASUVmax5 was an independent prognostic factor for relapse and mortality in patients with axillary lymph node -positive breast cancer who received NAC. 0 2021 Sociedad Espanola de Medicina Nuclear e lmagen Molecular. Published by Elsevier Espana, S.L.U. All rights reserved.en_US
dc.identifier.citationCan, C., Akdeniz, N., Kömek, H., Gündoğan, C., Urakçı, Z. ve Işıkdogan, A. (2022). The prognostic role of baseline F-18-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy. Revista Espanola de Medicina Nuclear E Imagen Molecular, 41(1), 3-10.en_US
dc.identifier.endpage10en_US
dc.identifier.issn2253-654X
dc.identifier.issue1en_US
dc.identifier.pmid34991833
dc.identifier.startpage3en_US
dc.identifier.urihttps://hdl.handle.net/11468/11311
dc.identifier.volume41en_US
dc.identifier.wosWOS:000741424000002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorUrakçı, Zuhat
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.language.isoenen_US
dc.publisherElsevier Espana SLUen_US
dc.relation.ispartofRevista Espanola de Medicina Nuclear E Imagen Molecular
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subject(18)FDG PET/CTen_US
dc.subjectNeoadjuvant chemotherapyen_US
dc.subjectSUVmax changeen_US
dc.subjectPrediction responseen_US
dc.subjectPrognosisen_US
dc.titleThe prognostic role of baseline F-18-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapyen_US
dc.titleThe prognostic role of baseline F-18-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu